T1	Participants 122 148	hepatocellular carcinomas.
T2	Participants 378 546	85 HCC patients after transcatheter arterial chemoembolization and radiofrequency ablation therapy were randomized to immunotherapy group and no adjuvant therapy group.
T3	Participants 757 864	All patients were screened by computed tomography every 2 months to observe the tumor recurrent conditions.
T4	Participants 1492 1504	HCC patients
